Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
680 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H2 2016, provides an overview of the Acute Lymphocytic Leukemia (Oncology) pipeline landscape. Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Acute Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 46, 42, 65 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 14 and 2 molecules, respectively.Acute Lymphocytic Leukemia. Acute Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (Oncology). - The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Acute Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 Introduction 7 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview 8 Therapeutics Development 9 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies 11 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 18 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance 20 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies 23 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes 34 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development 36 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment 126 Drug Profiles 148 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects 642 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products 649 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones 651 Appendix 659
List of Tables Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2016 29 Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H2 2016 30 Number of Products under Development by Companies, H2 2016 31 Number of Products under Development by Companies, H2 2016 (Contd..1) 32 Number of Products under Development by Companies, H2 2016 (Contd..2) 33 Number of Products under Development by Companies, H2 2016 (Contd..3) 34 Number of Products under Development by Companies, H2 2016 (Contd..4) 35 Number of Products under Development by Companies, H2 2016 (Contd..5) 36 Number of Products under Development by Companies, H2 2016 (Contd..6) 37 Number of Products under Investigation by Universities/Institutes, H2 2016 39 Comparative Analysis by Late Stage Development, H2 2016 40 Comparative Analysis by Clinical Stage Development, H2 2016 41 Comparative Analysis by Early Stage Development, H2 2016 42 Products under Development by Companies, H2 2016 43 Products under Development by Companies, H2 2016 (Contd..1) 44 Products under Development by Companies, H2 2016 (Contd..2) 45 Products under Development by Companies, H2 2016 (Contd..3) 46 Products under Development by Companies, H2 2016 (Contd..4) 47 Products under Development by Companies, H2 2016 (Contd..5) 48 Products under Development by Companies, H2 2016 (Contd..6) 49 Products under Development by Companies, H2 2016 (Contd..7) 50 Products under Development by Companies, H2 2016 (Contd..8) 51 Products under Development by Companies, H2 2016 (Contd..9) 52 Products under Development by Companies, H2 2016 (Contd..10) 53 Products under Investigation by Universities/Institutes, H2 2016 54 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 55 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H2 2016 56 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2016 57 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ADC Therapeutics SA, H2 2016 58 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Affimed GmbH , H2 2016 59 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Altor BioScience Corporation, H2 2016 60 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Inc., H2 2016 61 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016 62 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2016 63 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Array BioPharma Inc., H2 2016 64 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Atara Biotherapeutics, Inc., H2 2016 65 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 66 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bexion Pharmaceuticals, LLC, H2 2016 67 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H2 2016 68 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by BioSight Ltd., H2 2016 69 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 70 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2016 71 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Calithera Biosciences, Inc., H2 2016 72 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cantargia AB, H2 2016 73 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celgene Corporation, H2 2016 74 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectar Biosciences, Inc., H2 2016 75 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectis S.A., H2 2016 76 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016 77 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ceronco Biosciences, H2 2016 78 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cielo Therapeutics Inc, H2 2016 79 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016 80 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016 81 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 82 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by DiNonA Inc., H2 2016 83 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eli Lilly and Company, H2 2016 84 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by EpiZyme, Inc., H2 2016 85 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Erytech Pharma SA, H2 2016 86 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eureka Therapeutics, Inc., H2 2016 87 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Fate Therapeutics, Inc., H2 2016 88 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H2 2016 89 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gamida Cell Ltd., H2 2016 90 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H2 2016 91 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Hangzhou Minsheng Pharmaceutical Group Co.,Ltd, H2 2016 92 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by iDD biotech SAS, H2 2016 93 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Immunomedics, Inc., H2 2016 94 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Incyte Corporation, H2 2016 95 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Intech Biopharm Ltd, H2 2016 96 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Interprotein Corporation, H2 2016 97 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jasco Pharmaceuticals, LLC., H2 2016 98 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jazz Pharmaceuticals Plc, H2 2016 99 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Johnson & Johnson, H2 2016 100 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Juno Therapeutics Inc., H2 2016 101 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016 102 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kiadis Pharma N.V., H2 2016 103 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kite Pharma Inc, H2 2016 104 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Les Laboratoires Servier SAS, H2 2016 105 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by medac GmbH, H2 2016 106 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Merck & Co., Inc., H2 2016 107 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Mesoblast Limited, H2 2016 108 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 109 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Moleculin Biotech Inc, H2 2016 110 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Nanovalent Pharmaceuticals Inc., H2 2016 111 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Novartis AG, H2 2016 112 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NovImmune SA, H2 2016 113 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NuCana BioMed Limited, H2 2016 114 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Omeros Corporation, H2 2016 115 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoTartis, Inc., H2 2016 116 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoTherapy Science, Inc., H2 2016 117 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oncternal Therapeutics, Inc., H2 2016 118 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oribase Pharma, H2 2016 119 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OSE Immunotherapeutics, H2 2016 120 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfenex Inc., H2 2016 121 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfizer Inc., H2 2016 122 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pharma Mar, S.A., H2 2016 123 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Portola Pharmaceuticals, Inc., H2 2016 124 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Red5 Pharmaceuticals, LLC, H2 2016 125 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 126 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sanofi, H2 2016 127 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sareum Holdings Plc, H2 2016 128 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H2 2016 129 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sellas Inc, H2 2016 130 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Shire Plc, H2 2016 131 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 132 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Stemline Therapeutics, Inc., H2 2016 133 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by SYNIMMUNE GmbH, H2 2016 134 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Syros Pharmaceuticals Inc, H2 2016 135 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 136 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals, H2 2016 137 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Theravectys SA, H2 2016 138 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2016 139 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 140 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2016 141 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Verastem, Inc., H2 2016 142 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by VioQuest Pharmaceuticals, Inc., H2 2016 143 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Xbrane Biopharma AB, H2 2016 144 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ZIOPHARM Oncology, Inc., H2 2016 145 Assessment by Monotherapy Products, H2 2016 146 Assessment by Combination Products, H2 2016 147 Number of Products by Stage and Target, H2 2016 149 Number of Products by Stage and Mechanism of Action, H2 2016 157 Number of Products by Stage and Route of Administration, H2 2016 165 Number of Products by Stage and Molecule Type, H2 2016 167 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H2 2016 662 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..1), H2 2016 663 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..2), H2 2016 664 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..3), H2 2016 665 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..4), H2 2016 666 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..5), H2 2016 667 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..6), H2 2016 668 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, H2 2016 669 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products (Contd..1), H2 2016 670
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
